Analyses of cumulative expected lead and ALS case status in men
| Controls N (%) | Cases N (%) | OR (95% CI)* | aOR (95% CI)† | |
| No lag (n=93 508) | ||||
| No exposure | 78 975 (85.36) | 827 (83.87) | 1.00 (Ref) | 1.00 (Ref) |
| Ever exposure (µmol/L)‡ | 13 547 (14.64) | 159 (16.13) | 1.13 (0.95 to 1.33) | 1.15 (0.96 to 1.38) |
| <50.00 | 3172 (3.43) | 37 (3.75) | 1.19 (0.85 to 1.68) | 1.20 (0.85 to 1.69) |
| 50.00–222.00 | 3269 (3.53) | 33 (3.35) | 0.92 (0.63 to 1.34) | 0.93 (0.63 to 1.35) |
| >222.00 | 7106 (7.68) | 89 (9.30) | 1.22 (0.97 to 1.53) | 1.23 (0.99 to 1.55) |
| Test for trend | 1.01 (0.99 to 1.02) | 1.00 (0.99 to 1.02) | ||
| 5-year lag | ||||
| No exposure | 81 107 (87.66) | 848 (86.00) | 1.00 (Ref) | 1.00 (Ref) |
| Ever exposure (µmol/L)‡ | 11 415 (12.34) | 138 (14.00) | 1.16 (0.97 to 1.39) | 1.19 (0.98 to 1.44) |
| <50.00 | 3276 (3.54) | 39 (3.96) | 1.14 (0.83 to 1.58) | 1.22 (0.87 to 1.70) |
| 50.00–222.00 | 3348 (3.62) | 32 (3.25) | 0.92 (0.65 to 1.31) | 0.93 (0.64 to 1.35) |
| >222.0 | 4791 (5.18) | 67 (6.80) | 1.35 (1.05 to 1.73) | 1.35 (1.04 to 1.76) |
| Test for trend | 1.02 (0.99 to 1.04) | 1.01 (0.99 to 1.04) | ||
| 10-year lag | ||||
| No exposure | 81 802 (88.41) | 858 (87.02) | 1.00 (Ref) | 1.00 (Ref) |
| Ever exposure (µmol/L)‡ | 10 720 (11.59) | 128 (12.98) | 1.15 (0.95 to 1.38) | 1.16 (0.95 to 1.41) |
| <50.00 | 3208 (3.47) | 37 (3.75) | 1.11 (0.80 to 1.54) | 1.16 (0.83 to 1.64) |
| 50.00–222.00 | 3223 (3.48) | 32 (3.25) | 0.95 (0.67 to 1.36) | 0.95 (0.65 to 1.38) |
| >222.00 | 4289 (4.64) | 59 (5.98) | 1.32 (1.01 to 1.73) | 1.33 (1.03 to 1.72) |
| Test for trend | 1.01 (0.99 to 1.05) | 1.01 (0.98 to 1.04) | ||
Bold values are statistically significant (p <0.05)
*Controls were individually matched to cases on age and sex.
†Models adjusted for SES and residential location.
‡Cumulative expected exposure=level of exposure*days employed for jobs with >50% probability of exposure.
ALS, amyotrophic lateral sclerosis; aOR, adjusted OR; SES, socioeconomic status.